ClinicalTrials.gg
Active, not recruitingNCT06116786Updated Nov 3, 2026

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

A Phase 1 interventional study of JNJ-86974680 and Cetrelimab in Carcinoma, Non-small-Cell Lung, sponsored by Johnson & Johnson Enterprise Innovation Inc.. Active, not recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Johnson & Johnson Enterprise Innovation Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Updated Nov 3, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson — 7 open to participants now, 18 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Johnson & Johnson.

Enrollment
17th of 28
67 · median 70
Started
2023
with 2 others
Phase 1
6 of 36
none open now
Primary completion
2027-04
later than 9 of 17 live
Registered
28th of 36
by date

Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 1, reaches primary completion later than 9 of the 17 other live ones, and was the 28th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Read the detailed description

Study consists of a screening period, treatment period (Part 1: dose escalation and Part 2: dose expansion), post-treatment follow-up period, and long-term extension period.

03

Conditions studied

  • Carcinoma, Non-small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
  • Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], c-ros oncogene 1 [ROS1], v-raf murine sarcoma viral oncogene homolog B1 [BRAF]) must have received all approved targeted therapies and have progressed
  • Part 2: No targetable mutations (for example, EGFR [epidermal growth factor receptor], ALK [anaplastic lymphoma kinase], ROS1[c-ros oncogene 1], and BRAF [B-Raf proto-oncogene, serine/threonine kinase])
  • Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 () or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
  • For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for disease as the
  • For Cohort C of Part 2: Treatment naïve
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) disease involvement
  • Active disease
  • Active infection
  • History of solid organ or hematologic stem cell transplantation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Part 1: JNJ-86974680+Cetrelimab

    Participants will receive JNJ-86974680 alone (dose 1, dose 2, dose 3, and dose 4) daily in 4 cohorts and then along with a set dose of cetrelimab.

    Drug: JNJ-86974680 · Drug: Cetrelimab

  • Experimental
    Part 2: JNJ-86974680+Cetrelimab+Radiation Therapy (RT)

    Part 2 will consist of 3 cohorts (A, B and C) and participants will receive treatment with the selected dose of JNJ-86974680 in combination with cetrelimab from part 1, in conjunction with radiation.

    Drug: JNJ-86974680 · Drug: Cetrelimab · Radiation: Radiation Therapy

Interventions

  • DrugJNJ-86974680

    JNJ-86974680 will be administered.

  • Cetrelimab will be administered.

  • RadiationRadiation Therapy

    Radiation therapy will be administered.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) by Severity

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

    Time frame: Up to 2 years 5 months

  2. Number of Participants with Dose Limiting Toxicities (DLTs)

    The DLTs are specific adverse events and are defined as any of the following: non-hematologic toxicity and hematological toxicity.

    Time frame: Up to 2 years 5 months

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of JNJ-86974680

    Cmax is defined as maximum observed plasma concentration of JNJ-86974680.

    Time frame: Up to 2 years 5 months

  2. Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t) of JNJ-86974680

    (AUC0-t) is defined as area under the plasma concentration of JNJ-86974680 versus time curve from the time of dose administration to time of last quantifiable concentration (0-t).

    Time frame: Up to 2 years 5 months

  3. Part 2: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v)1.1, maintained for at least 4 weeks.

    Time frame: Up to 2 years 5 months

  4. Part 2: Complete Response Rate (CRR)

    CRR is defined as the proportion of participants with a best response of CR.

    Time frame: Up to 2 years 5 months

  5. Part 2: Duration of Response (DOR)

    DoR is defined as the time from the date of first initial documentation of a response to the date of first documented evidence of progression of disease according to immunotherapy response evaluation criteria in solid tumors (iRECIST) or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years 5 months

  6. Part 2: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieve a best of response of PR, CR, or stable disease using RECIST v1.1.

    Time frame: Up to 2 years 5 months

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Apr 2027, 40 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 40 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

Completion moved twice since we started tracking on Sep 25, 2026: Jun 2029 → Jan 2028, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 3, 2023
StartActual
Nov 27, 2023
Primary completionEst.
Apr 14, 2027
CompletionEst.
Jan 31, 2028was Jun 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jun 7, 2029→Jan 31, 2028
moved 2 times, Sep 25, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Study completion Nov 30, 2027→Jan 31, 2028
    + 1 other change: verification date
  2. Sep 25, 2026
    Study completion Jun 7, 2029→Nov 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06116786
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Nov 27, 2023
Primary completion
Apr 14, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Johnson & Johnson Enterprise Innovation, Inc Clinical Trial
study director · Johnson & Johnson Enterprise Innovation Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetrelimab

Start the discussion